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ABSTRACT 
Background: Perioperative goal directed fluid therapy (GDFT) has been shown to reduce 
postoperative complications following major surgery; this intervention has not been formally 
evaluated in the setting of liver transplantation. 
 
Methods: We conducted a prospective trial of GDFT following liver transplantation 
randomising patients with liver cirrhosis to either 12 hours of GDFT using non-invasive cardiac 
output monitoring or standard care (SC). The primary outcome was feasibility. Secondary 
outcomes included survival, postoperative complications (Clavien-Dindo), quality of life (by 
EQ-5D-5L) and resource use. Trial specific follow up occurred at 90 and 180 days after 
surgery.  
 
Results: The study was feasible. Of 224 eligible patients,122 were approached,114 consented 
to participate and 60 were enrolled into the trial. The mean (SD) volume of IV crystalloid 
administered to the GDFT group during the 12-hour study period was 3968 (2073) ml for the 
GDFT group and 2510 (1026) ml for the SC group. As regards secondary outcomes there was 
no difference in survival or overall complication rates. There was no significant difference in 
quality of life scores and resource use between the groups.  
 
Conclusion: A randomised study of GDFT following liver transplantation is feasible. A post-
trial stakeholder meeting supported proceeding with a full multi-centre trial.  
 
Abstract word count: 199  
 
Trial registration: International Standard Randomised Controlled Trial Registry, ID: 
ISRCTN10329248. Registered on 4 April 2016. 
 
INTRODUCTION 
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The volume and type of intravenous (IV) fluid that is given around the time of surgery as well 
as the manner in which it is administered directly affects patient outcomes.1 Under-
resuscitation can result in organ hypoperfusion and failure2 whilst excessive IV fluid is equally 
harmful.3, 4 One method of optimising fluid administration is goal-directed fluid therapy (GDFT), 
defined as the administration of IV fluid boluses to restore intravascular normovolaemia 
against a specific haemodynamic target.5 Perioperative GDFT can be undertaken during 
and/or after surgery. Patients undergoing major surgery have been shown to benefit from 
perioperative stroke volume optimisation by GDFT, primarily in terms of reduced postoperative 
complications and length of hospital stay.6–8 These advantages lead to improvements in 
postoperative quality of life, increased life expectancy and reduced costs to healthcare 
providers.9–11 Estimation of a patient’s intravascular volume status based on simple measures 
such as heart rate, blood pressure, central venous pressure and urine output is known to be 
inaccurate but remains standard of care during and after the majority of surgical procedures12, 
13 including liver transplantation. In patients with liver cirrhosis presenting for transplantation 
cirrhotic cardiomyopathy is common and can have a profound impact on cardiovascular 
function perioperatively.14 The findings from GDFT studies in patients undergoing general 
abdominal surgery may therefore not be applicable to those requiring liver transplantation.  
We undertook a feasibility randomised controlled trial (RCT) to assess the ability to enrol 
patients into a study of postoperative GDFT, successfully deliver the intervention and evaluate 
its safety profile in patients with liver cirrhosis undergoing transplantation.  
 
METHODS 
Study design  
The protocol for this study has been published previously.15 We conducted an RCT of GDFT 
versus standard IV fluid management in a single centre in the United Kingdom to assess the 
feasibility of conducting a postoperative fluid optimisation trial in patients who have undergone 
liver transplantation. Secondarily, we compared the intervention and standard care (SC) 
groups to assess the safety profile of GDFT and to collect information on clinical outcomes 
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and quality of life, evaluated potential primary outcomes for a subsequent trial to assess the 




The study was reviewed and approved by University College London Bloomsbury Research 
Ethics Committee. Potential participants were identified from the liver transplantation waiting 
list or preoperative assessment clinic. Inclusion and exclusion criteria are shown in Table 1. 
All patients provided written consent. Following liver transplantation, at the time of admission 
to the intensive care unit (ICU), patients were randomised in a 1:1 manner into either the 
GDFT or SC group. The Sealed Envelope randomisation service was used to allocate 
patients.  Randomisation was stratified according to whether the organ donor was deceased 
after cardiac death (DCD) or deceased after brain death (DBD). The donor retrieval and 
surgical implantation procedures used are outlined in the supplementary material.  
 
Study intervention 
GDFT or SC was commenced postoperatively on arrival to the ICU and continued for a total 
of 12 hours. In both groups, the participants were connected to an EV1000 Clinical Platform 
via a FloTrac transducer (Edwards Life Sciences, Irvine, USA) to provide continuous 
haemodynamic monitoring. All EV1000 data were recorded by a designated research nurse. 
In the GDFT group a protocol was used to optimise intravascular fluid volume (Figure 1). This 
protocol, administered by the trial research nurse, was initiated by giving a 250 ml bolus of IV 
Hartmann’s solution over 5-10 minutes. If the SV increased by 10% or more after the bolus 
the participant was deemed to be fluid responsive, and a further monitored bolus was 
administered. The administration of fluid boluses was repeated until a rise of 10% or greater 
was no longer observed. Monitoring then continued until the SV fell by 10% or greater from 
this baseline; the bolus procedure was then repeated. No continuous maintenance IV fluid 
was given to patients in the GDFT group. All intervention fluid boluses were given by the 
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research nurse and the volume recorded on the bedside chart so that it could be seen by the 
clinical team. For participants in the SC group the research nurse documented haemodynamic 
variables from the EV1000 hourly but this information was blinded to the clinical team and the 
research nurse did not administer any IV fluid to participants. In the SC group, fluids were 
administered by the clinical team without information from the haemodynamic monitoring. In 
both groups, clinicians could administer additional IV fluids if they deemed it to be necessary; 
these choices were documented for the period of the intervention. All other medical 
management was similar between the two treatment groups, including the administration of 
blood products, which was not protocolised. At the end of the 12 hour study period, the 
EV1000 monitor was disconnected and the clinical team instructed to continue IV fluid 
management as they deemed clinically appropriate.  
 
Outcome measures 
The primary outcome of the study was feasibility, assessed using the following metrics: 
participant recruitment rate, protocol completion and deviations, and participant withdrawal. A 
predetermined recruitment of greater than 40% of patients fulfilling the criteria for this study 
was deemed to indicate success. A number of predetermined secondary outcomes were also 
measured (Table 2)15, including postoperative complications16. Quality of life (QoL) was 
assessed by asking participants to complete an EQ-5D-5L assessment immediately prior to 
surgery, at discharge from hospital, and 90 and 180 days after surgery. Resource use data 
were collected during hospital admission and at the two follow-up points.  
 
Statistical analysis  
Data were collected onto a paper collection form and then transferred onto an electronic 
clinical record form (eCRF) – REDCap (Research electronic data capture17). Statistical 
analyses were carried out with STATA version 14 with the statistician blinded to the treatment 
arm. The two treatment groups were compared to ensure they had similar clinical 
characteristics using mean and standard deviation or median and inter-quartile range for 
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continuous variables, as appropriate, and counts and percentages for categorical variables. 
For feasibility outcomes, the proportion of patients who consented to be randomised was 
presented with a 95% confidence interval. The proportion of patients withdrawn from GDFT 
was also presented as well as the proportion of patients who deviated from the GDFT protocol 
for the 12 hour intervention period. For clinical outcomes, the difference in the proportion of 
people with a complication between the two groups was calculated with a 95% confidence 
interval. The median number and grade of complications were also presented. The median 
length of stay in ICU and hospital was presented for each group while the proportion of patients 
readmitted in ICU during the whole period of follow-up was also calculated. The mean 
difference in quality of life score between the two groups at each time point was presented 
with a 95% confidence interval. All other secondary outcomes were summarised for each 
group using mean profile plots over time and mean/median differences at baseline, 6 and 12 
hours were presented as appropriate with 95% confidence intervals.  
 
Economic analysis 
For the economic analysis data on healthcare resources, patient survival and QoL were 
utilised. The EQ-5D-5L data were converted to an EQ-5D index score using a crosswalk 
algorithm.18 Quality adjusted life years (QALYs) was further estimated by multiplying index 
scores by corresponding duration. Costs per patient was estimated based on resource use 
during the primary (transplant surgery) admission and subsequent healthcare usage. 
Multiplying the unit costs by each unit of resource use and summing these resource costs 
across each patient’s six-month follow-up from date of operation enabled aggregation of total 
cost per patient. A value of 0 was assigned to resource use and utility after death if a patient 
died during trial period. Where possible, national estimates of unit prices was sourced from 
the NHS Reference Costs published by Department of Health (DH, 2017) and Personal Social 
Services Research Unit (PSSRU, 2017) to apply to resource use data from the COLT trial. 
The ICU cost was weighted by activity to calculate adult critical care costs for patients with 
liver disease. The cost of IV fluid replacement immediately following liver transplantation using 
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GDFT were identified from the hospital personnel including the cost of the EV1000 monitor 
and FloTrac transducers. 
 
RESULTS 
Patient enrolment  
The study recruited patients from March 2016 - July 2017. The initial planned study size was 
50 participants which was increased to 60 as the baseline QoL assessment was incomplete 
in the early stages of the study. A total of 224 eligible patients were sent a patient information 
sheet and of these 122 were formally approached either in an outpatient clinic or on the day 
of surgery (Figure 2). Of the 122 patients approached 114 consented to participate (93.4%, 
95% confidence interval (CI) 87.5 to 97.1%) and 8 declined. None withdrew their consent. Of 
the 114 consented patients on the waiting list, 60 proceeded to transplant during the trial 
recruitment period and enrolled into the study. The reason that 54 consented patients were 
not randomised were: not undergoing transplant within the trial period (n=25), removed from 
the waiting list for clinical reasons (n=14), research team not available (n=9), enrolled into 
another RCT (n=5) and died on the transplantation waiting list (n=1). The median recruitment 
rate was 4 participants per month. The median (IQR) age of participants was 53.2 (10.9) years, 
and 43/60 (71.7%) were female. The recipient baseline and donor characteristics according 
to treatment group are shown in Table 3.  
 
Intervention period 
All patients completed the 12 hour trial treatment. There were seven protocol deviations in the 
GDFT group and one in the SC group; all were deemed to be minor deviations. No participants 
were withdrawn from the trial treatment at the request of the clinical team 
 
There was no difference in heart rate, systolic blood pressure, SV, cardiac output or cardiac 
index between the two groups at baseline, hour 6 or hour 12 post-transplant. Diastolic blood 
pressure was higher in the GDFT group at baseline (62.7 (10.19)) versus 55.3 (9.11) mmHg 
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(mean difference: 7.4 (95%CI: 2.41 to 12.39)), but not at 6 or 12 hours. The mean difference 
in cardiac output change from baseline to hour 6 between the two groups was -1.53 l (95% 
CI: -2.95 to -0.11), mixed venous oxygen saturation was higher in the SC group at 12 hours 
(77.57 % (4.86) versus 69.9 (6.97), mean difference: -7.67 (95%CI: -14.2 to -1.15)) although 
there were only 7 and 10 patients with these data in respective groups. Mean haemodynamic 
measures during the 12 hour treatment period are shown for each group in the supplementary 
material.  
 
Trial treatment  
The mean (SD) volume of IV crystalloid fluid administered to the GDFT group during the 
treatment period was 3968 (2073) ml for the GDFT group and 2510 (1026) ml for the SC 
group. Additional fluid and blood products administered to participants is detailed in Table 4; 
the mean (SD) total fluid volume administration (including blood products) during the treatment 
period was 5316 (2334) ml for the GDFT group and 3807 (1345) ml for the SC group.  
 
Completeness of follow up data collection 
Clinical follow up data was complete for 60/60 (100%) at hospital discharge, 58/58 (100%) at 
90 days and 56/57 (98.3%) at 180 days. For QoL data this was 55/58 (94.8%), 56/57 (98.2%) 
and 56/57 (98.2%) respectively.  
 
Secondary outcomes  
There were no differences in the mortality rate and overall number and severity of 
complications between the 2 groups (Table 5). Grade III complications (those requiring 
intervention) were increased in the GDFT group (19 (63.3%) versus 6 (20%), difference in 
proportion: 43.3 (95%CI: 20.9 to 65.7)). The detailed breakdown of complications is shown in 
the supplementary online data. Most complications occurred during the postoperative hospital 
stay.  
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Dividing the complications into organ-specific domains according to the postoperative 
morbidity survey (POMS) classification19 there were no differences between the two groups 
during their hospital admission. At 90 days there were more neurological complications in the 
GDFT group than the SC group (11 (40.7%) versus 1 (3.6%), difference in proportion: 37.2 
(95% CI: 17.4 to 56.9)). At 180 days there were more cardiovascular complications in the SC 
than the GDFT group (8 (30.8%) versus 1 (3.6%), difference in proportion: -27.2% (-46.2 to -
8.2). Liver transplantation-specific complications in each group are shown in the 
supplementary material. The total number of patients with at least one liver transplantation-
specific complication was not different between the groups at discharge from hospital, 90 day 
or 180 days. There were 6 (20%) occurrences of biliary leak requiring intervention in the GDFT 
group compared to 1 (3.3%) in the SC group (difference in proportion: 16.7 (95%CI: 1 to 32.4)).   
 
The median ICU length of stay was 3.5 (3-10) days in the GDFT group and 3.0 (2-8) days in 
the SC group (p=0.673); median hospital length of stay was 26.0 (18-41) days for the GDFT 
group and 23.0 (15-30) days for the SC group (p=0.473). Five patients had at least one 
readmission to ICU from GDFT (16.7%) group and three (10%) from the SC group, but this 
not statistically significant (difference in proportion: 6.7% (95%: -10.5 to 23.8).  
 
Economic Analysis 
A total of 13 patients, 5 from GDFT group and 8 from SC group had one or more missing EQ-
5D assessment or resource use at different time points. Complete case analysis was adopted 
to estimate incremental QALY and incremental cost for each patient. This approach reduced 
the sample size to 25 patients in GDFT group and 22 patients in SC group. A summary of 
utility estimates for the two arms over the trial period is provided in Table 6. The QoL score in 
the GDFT group was lower than the SC group at each time period. However, the difference in 
score between the two groups was not statistically significant at any time point. 
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The QALY for the GDFT and SC groups over the trial period is summarised in Table 7. In the 
six-month follow up, the average QALYs in the GDFT group were slightly lower than in the SC 
group. The difference was -0.014 and was not statistically significant (p=0.68). 
 
The mean inpatient stay in GDFT group was lower than the SC group in term of length of stay 
(Table 8). The difference in resource use was not statistically significant at any time point. The 
average cost of inpatient stay during primary admission and six-month follow up for GDFT 
group was £59,233, which was lower than the SC group at £60,743. However, the difference 
of £1,509 was not statistically significant.  
 
DISCUSSION 
We set out to determine whether it was feasible to carry out a study of postoperative GDFT in 
patients with liver cirrhosis who had undergone liver transplantation. We successfully recruited 
93.4% of approached patients, without any being withdrawn from the study and with few 
protocol deviations. Compliance with follow-up data collection was 95% or more of the 
participants at 180 days. This demonstrates that under trial conditions, GDFT can be delivered 
on an ICU following liver transplant surgery. The principle finding was that patients were 
extremely motivated to participate in research of this nature. We enrolled a median of 4 
participants per month, which compares favourably to the median of less than 1 per month 
found in a recent review of UK NIHR funded trials.20 GDFT was considered acceptable to 
clinicians as no patients had their study treatment terminated. 
 
During the 12 hour treatment period the median volume of crystalloid received by the GDFT 
group was greater than received by the SC group. A previous retrospective ‘before and after’ 
study of GDFT in liver transplant showed reduced fluid administration and improved clinical 
outcomes with 48hrs of GDFT.21 Differences may be due to the non-randomised nature of the 
previous study or the increased duration of GDFT. Whether optimal fluid balance 
perioperatively improves clinical outcomes remains debatable.4, 22 Some of this debate is due 
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to lack of clarity of definitions along with poor study design.23 A ‘zero-balance’ approach has 
been advocated for patients in enhanced recovery after surgery programmes24 and weight 
gain postoperatively (due to fluid accumulation) can lead to an increase in complications and 
hospital length of stay.25 A cumulative positive postoperative fluid balance following liver 
transplant has also been independently associated with the development of acute kidney 
injury and a requirement for renal replacement therapy.26 Whilst there were few statistical 
differences between the GDFT and SC groups in haemodynamic measures collected during 
the study intervention period, there were a number of interesting trends that suggest a positive 
effect of the intervention during that time (see supplementary online material).  
 
This study was not powered to detect differences in secondary outcomes between study 
groups. However, they were calculated in order to assess their value as endpoints for future 
studies and to identify any possible harms associated with the intervention. In terms of 
postoperative complications, there were no overall differences in number and severity of 
complications between the groups. Increased incidences within small sub-groups, such as 
those with grade 3 complications or with bile leaks, are likely to be related to the small patient 
numbers involved. This would, however, have to be reviewed within the context of a larger 
trial. 
 
The optimal period and duration of GDFT remains unclear. We anticipated that intraoperative 
GDFT would not be possible due to the rapidly changing haemodynamic landscape during 
transplant surgery. This is not to say that it will never be possible and the previously mentioned 
study has to some extent explored its feasibility during transplant surgery.21 The type of device 
used to measure haemodynamic variables varies widely between studies and it is not clear 
whether benefits demonstrated with one technology can be translated to other technologies.27, 
28 We elected to use an uncalibrated pulse contour analysis device, the EV1000 FloTrac 
system (Edwards Life Sciences, Irvine, USA) as all patients undergoing liver transplant would 
have an arterial catheter inserted as part of routine clinical practice. A similar device, the 
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FloTrac-Vigileo (Edwards Lifesciences, Irvine, USA) has been compared alongside a 
calibrated pulse contour analysis monitor (LiDCO Plus - LiDCO Ltd., London, UK) and neither 
performed well compared to pulmonary artery catheter thermodilution measurements of 
cardiac index during orthotopic liver transplant.29 It has previously been reported that the 
FloTrac-Vigileo had clinically acceptable bias and precision when compared to pulmonary 
artery catheter thermodilution in patients undergoing liver transplant, although it 
underestimated pulmonary artery catheter measurements at higher cardiac outputs.30  
 
QoL assessed by the EQ-5D-5L indicated a slightly lower utility estimate for patients at all time 
periods and lower QALY value with GDFT than the SC group. However, these differences 
were not significant. In terms of overall hospital resource use, the total costs were lower for 
the GDFT group because of a shorter inpatient stay compared to SC group. Due to some 
missing QoL observations a complete case analysis was conducted. However, this approach 
could allow a selection bias for complete data in those with a better QoL score. For example, 
a patient who died during follow up was excluded from the complete case analysis because 
the resource use data before death was unavailable. The economic analysis was preliminary 
and should be investigated in a larger sample size in the future. 
 
One of the major strengths to this study is that in the GDFT group the fluid was administered 
by the trial research nurse according to the pre-defined protocol and in the SC group the 
cardiac output data were collected but the data was hidden from the clinical team. This 
minimised the risk of bias in fluid management. However, the clinical team would be aware 
which arm of the study the patient had entered and hence it was felt necessary to declare all 
fluid boluses and record them on the patient’s clinical chart. Thus, unidentified confounding 
factors could have influenced the results of the study. Importantly, those analysing the data 
were blinded to the allocated group of the participants in the database. Another limitation is 
that the study was only conducted in a single centre, a design which is known to lead to a 
larger intervention effect than multicentre studies.31 Relevant to our feasibility outcome is the 
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fact that single-centre studies in the UK tend to have a higher recruitment rate than the 
individual sites of multicentre studies.20 There were more protocol deviations in the GDFT 
group compared to the SC group, which was not a surprising finding as the protocol for the 
intervention in the GDFT group was complicated compared to SC group. All of the deviations 
were determined to be minor, so are unlikely to have exerted a significant impact on the 
results.  
 
In conclusion we have demonstrated the feasibility of conducting a study of postoperative 
GDFT in patients with cirrhosis following orthotopic liver transplantation. Although some 
complications were more common with GDFT the overall complication rate was no different 
to SC. In this feasibility study we were unable to ascertain whether or not GDFT was of clinical 
benefit as this was not the purpose of the trial. A stakeholder meeting with patient 
representatives supported proceeding to a larger multicentre study to demonstrate efficacy 
and cost effectiveness. 
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TABLES 
Table 1. Study inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
Adult patients (aged between 18 and 80 
years) 
Non-cirrhotic liver disease   
Diagnosis of liver cirrhosis  Pregnancy   
Selected to undergo liver transplantation 
at the Royal Free Hospital 
Age less than 18 years or over 80 years   
Competent to give consent Body weight less than 40 kg   
 Re-transplantation for primary graft non-
function   
 Fulminant hepatic failure   
 Emergency surgery   
 Known learning disabilities or previously 
lacking capacity to consent for 
themselves   
 
 Prisoners   
 Patients already enrolled in an 
interventional study 
 Refusal or inability to consent 
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Table 2. Secondary outcome measures 
Secondary outcome measures 
Quality of life scores: at hospital discharge, 90 and 180 days post-surgery 
Length of ICU stay (days) 
Length of hospital stay (days) 
Survival: at hospital discharge, 90 and 180 days 
Postoperative complications: at hospital discharge, 90 and 180 days *  
Specific liver transplantation-related complications: at hospital discharge, 90 
and 180 days 
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Table 3. Recipient baseline and donor characteristics 
 GDFT group (n=30) SC group (n=30) 
Recipient baseline details 
Mean (SD) Age 51.16 (10.4) 54.7 (11.2) 
Male (%) 20 (66.7%) 23 (76.7%) 
Recipient MELD 15.4 (5.6) 15.0 (5.4) 
Recipient UKELD 54.5 (4.7) 54.0 (4.9) 
EQ-5D-5L* (n=54) 0.8 (0.2) 0.8 (0.1) 
Reason for transplantation 
Alcohol-related cirrhosis 11 (36.7%) 12 (40.0%) 
Hepatitis C 3 (10.0%) 9 (30.0%) 
Hepatitis B 4 (13.3%) 2 (6.7%) 
Autoimmune hepatitis 2 (6.7%) 1 (3.3%) 
Primary biliary cirrhosis 6 (20%) 4 (13.3%) 
Primary sclerosing cholangitis 2 (6.7%) 0 (0%) 
other 9 (30%) 10 (33.3%) 
Donor details 
Donor Age (years) † 49.8 (17.3) 44.9 (18.9) 
Donor BMI† 25.6 (4.2) 24.6 (3.8) 
Cold Ischaemic time (hours)† 7.2 (2.6) 7.3(2.7) 
DBD [heart beating] (%) 24 (80.0%) 25 (83.3%) 
DCD [non-heart beating] (%) 6 (20.0%) 5 (16.7%) 
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Donor Liver Appearance* 
  Healthy 







Donor Liver Steatosis* 
  None 
  Mild 









Donor Liver Capsular Damage* 2 (7.1%) 4 (13.3%) 
Graft Type 
  Split liver 








  Conventional 








Data is presented in Means and SD 
† 1 missing value in GDFT group for donor age, BMI and CIT 
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Table 4. Mean (SD) intravenous fluid and blood products administered during the study 
intervention period  
 GDFT group SC group 
Crystalloid (ml) 3968 (2073) 2510 (1027) 
Additional fluid volume (ml)* 864 (609) 779 (473) 
Total fluid input (ml) 5317 (2335) 3807 (1345) 
Blood products  
20% Human Albumin 
Solution (ml) 
93 (295) 74 (209) 
Packed red blood cell (ml) 177 (456) 150 (316) 
Fresh frozen plasma (ml) 81 (233.7) 145 (323) 
Cryoprecipitate (ml) 71 (394.0) 73 (157) 
Platelets (ml) 62 (175) 76 (165) 
 
* primarily fluid used to dilute intravenous medications 
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Table 5. Number (%) of patients in each group with at least one complication by Clavien-Dindo 
grade during their hospital admission.  
 








N Freq (%) Difference in 
proportion (95%CI) 
p-value 
Discharge I 30 27 (90) 30 26 (86.7) 3.33% (-12.89 to 
19.56) 
0.688 
 II 30 17 
(56.7) 
30 22 (73.3) -16.67% (-40.43 to 
7.1) 
0.176 
 III 30 19 
(63.3) 
30 6 (20.0) 43.33% (20.92 to 
65.74) 
0.001 
 IV 30 16 
(53.3) 
30 14 (46.7) 6.67% (-18.58 to 
31.91) 
0.606 
 V 30 1 (3.3) 30 1 (3.3) 0% (-9.08 to 9.08) 0.754 
         
90 days I 27 24 
(88.9) 
28 19 (67.9) 21.03% (0.06 to 42) 0.059 
 II 27 16 
(59.3) 
28 17 (60.7) -1.46% (-27.35 to 
24.44) 
0.912 
 III 27 7 (25.9) 28 8 (28.6) -2.65% (-26.17 to 
20.88) 
0.826 
 IV 27 1 (3.7) 28 0 (0) 3.7% (-3.42 to 10.83) 0.304 
 V 27 0 (0) 28 1 (3.6) -3.57% (-10.45 to 
3.3) 
0.509 
         
180 days I 28 15 
(53.6) 
26 15 (57.7) -4.12% (-30.61 to 
22.37) 
0.761 
 II 28 12 
(42.9) 
26 7 (26.9) 15.93% (-9.1 to 
40.97) 
0.221 
 III 28 9 (32.1) 26 8 (30.8) 1.37% (-23.4 to 
26.15) 
0.914 
 IV 28 0 (0) 26 0 (0) /  
 V 28 0 (0) 26 0 (0) /  
        
Total 
period 
I 30 30 (100) 30 28 (93.3) 6.67% (-2.26 to 
15.59) 
0.246 
 II 30 27 (90) 30 27 (90) 0% (-15.18 to 15.18) 0.665 
 III 30 23 
(76.7) 
30 19 (63.3) 13.33% (-9.61 to 
36.28) 
0.260 
 IV 30 16 
(53.3) 
30 14 (46.7) 6.67% (-18.58 to 
31.91) 
0.606 




GDFT = Goal directed fluid therapy; SC = standard care  
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Table 6. Quality of life measured by EQ-5D index score 
 GDFT group SC group  
Variable Obs. Mean (a) Std. Dev. Obs. Mean (b) Std. Dev. Difference (a-b) 
Baseline 25 0.799 0.18 22 0.821 0.14 -0.022 
Discharge 25 0.641 0.32 22 0.642 0.24 -0.001 
90 day 25 0.698 0.29 22 0.746 0.26 -0.047 
180 day 25 0.726 0.30 22 0.780 0.22 -0.055 
 




Table 7. Mean QALY by treatment group arm 
QALY Obs. Mean 95% CI 
GDFT group 25 0.350 0.30 to 0.41 
SC group 22 0.365 0.32 to 0.41 
Difference  -0.014 -0.84 to 0.06 
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Table 8. Mean number and type of hospital bed days by arm. 
 GDFT group SC group  
Variable Obs. Mean (a) 
Std. 
Dev. 
Obs. Mean (b) Std. Dev. Difference (a-b) 
ICU 25 6.8 10.4 22 6.8 8.7 0 
Ward 25 13.6 10.3 22 15.7 12.1 -2.1 
ICU at 90 day 25 6.2 10.3 22 6.3 8.8 -0.1 
Ward at 90 day 25 19.7 14.6 22 21.0 14.6 -1.3 
ICU at 180 day 25 6.2 10.3 22 6.3 8.8 -0.1 
Ward at 180 day 25 23.1 16.1 22 22.8 16.0 0.3 
 
ICU = intensive care unit; GDFT = Goal directed fluid therapy; SC = standard care  
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